Resources

Tokyo, Japan, 22 January, 2026 - FRONTEO, Inc. and TAGCyx Biotechnologies Inc. , a start-up biotech company developing innovative pharmaceuticals and diagnostic technologies using artificial nucleic acid aptamers based on artificial base technology, are pleased to announce that we concluded a PoC feasibility agreement to explore new therapeutic targets and indications for artificial nucleic acid aptamers developed by TAGCyx Bio using Drug Discovery AI Factory provided by FRONTEO.

Tokyo, Japan, December 23, 2025 - FRONTEO, Inc. (FRONTEO; Headquarters, Tokyo, Chief Executive Officer, Takahiro Morimoto) announced that FRONTEO and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) have launched a co-creation project aimed at discovering the therapeutic targets for rare diseases.

Combining strengths in target molecule discovery and compound generation and optimization to create novel drug discovery opportunities

Tokyo, Japan, October 1, 2025 - FRONTEO, Inc. announced that, it has entered into two Proof of Concept (PoC) research agreements with NB Health Laboratory Co., Ltd. (Headquarters: Sapporo, Japan; President: Kiyoshi Takayama; hereinafter “NBHL”), a company dedicated to discovering and developing antibody drugs

Tokyo, Japan, 26 August 2025 - FRONTEO, Inc. announced that it gave an oral presentation at the 42nd Annual Conference of the Society of Japanese Oriental Medicine held from August 23 to 24, 2025, on the theme of exploring the mechanism of action of Hochuekkito, a traditional Kampo formula.

Tokyo, Japan, 18 August 2025 - FRONTEO, Inc. announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) for analysis services leveraging FRONTEO’s AI drug discovery support platform, Drug Discovery AI Factory (“DDAIF”)1. The agreement covers analysis of Daiichi Sankyo’s toxicology study databases and the text content of toxicology study reports.

Tokyo, Japan, 5 August, 2025 - FRONTEO, Inc. and NICCA Chemical Co., Ltd. announced the launch of a co-creation project to explore novel targets in the cosmetics domain. This initiative leverages FRONTEO’s AI drug discovery support service, Drug Discovery AI Factory (“DDAIF”), to accelerate research and development of new products using effective cosmetic ingredients.

Tokyo, Japan, July 23, 2025 - FRONTEO, Inc. announced that, using its AI drug discovery support service Drug Discovery AI Factory (hereinafter “DDAIF”) , it has identified candidate drug discovery target molecules for pancreatic cancer, and confirmed that they inhibit cancer cell proliferation in vitro (test‑tube) experiments.

Tokyo, Japan, July 23, 2025 - FRONTEO, Inc. announced that, FRONTEO and the University of Oklahoma have begun a joint research project to explore new drug targets and drug repositioning, utilizing the unique technologies and research capabilities. This is the first step towards the development of FRONTEO's AI drug discovery business in the United States.

Tokyo, Japan, 9 July, 2025 -Fuji Pharma Co., Ltd. and FRONTEO, Inc.  today announced the launch of a co-creation project to evaluate drug discovery seeds, new drug candidates, in the field of women's health care, utilizing FRONTEO's AI drug discovery support service, Drug Discovery AI Factory (hereinafter "DDAIF").

Tokyo, Japan, 30 June, 2025 -Metagen Therapeutics, Inc. and FRONTEO, Inc. are pleased to announce the launch of a joint research collaboration applying the microbiome— an area of growing global attention—to drug discovery, using FRONTEO’s AI drug discovery support service, the “Drug Discovery AI Factory” (hereinafter “DDAIF”).

Tokyo, Japan, June 25, 2025 - FRONTEO, Inc. announced that it has signed a strategic partnership agreement with Q Partners LLC, a U.S. consulting firm with expertise in the life sciences industry.